These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27423423)

  • 41. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
    Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
    J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
    Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
    J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.
    Moreno P; Jiménez-Jiménez C; Garrido-Rodríguez M; Calderón-Santiago M; Molina S; Lara-Chica M; Priego-Capote F; Salvatierra Á; Muñoz E; Calzado MA
    Mol Oncol; 2018 Oct; 12(10):1778-1796. PubMed ID: 30099851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
    Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
    J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.
    de Castro J; Rodríguez MC; Martínez-Zorzano VS; Sánchez-Rodríguez P; Sánchez-Yagüe J
    Am J Clin Pathol; 2014 Jul; 142(1):111-20. PubMed ID: 24926094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis.
    Chen X; Hu Z; Wang W; Ba Y; Ma L; Zhang C; Wang C; Ren Z; Zhao Y; Wu S; Zhuang R; Zhang Y; Hu H; Liu C; Xu L; Wang J; Shen H; Zhang J; Zen K; Zhang CY
    Int J Cancer; 2012 Apr; 130(7):1620-8. PubMed ID: 21557218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A metabolomic approach to lung cancer.
    Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
    Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differentiating Small-Cell Lung Cancer From Non-Small-Cell Lung Cancer Brain Metastases Based on MRI Using Efficientnet and Transfer Learning Approach.
    Grossman R; Haim O; Abramov S; Shofty B; Artzi M
    Technol Cancer Res Treat; 2021; 20():15330338211004919. PubMed ID: 34030542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
    Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC.
    Zheng CX; Zhao SX; Wang P; Yu HM; Wang CF; Han B; Su B; Xiang Y; Li XS; Li SX; Ma QY; Zhang RX; Wan HY; Song HD
    Oncol Rep; 2009 Nov; 22(5):1057-61. PubMed ID: 19787221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
    Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
    J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolomic prediction of endometrial cancer.
    Bahado-Singh RO; Lugade A; Field J; Al-Wahab Z; Han B; Mandal R; Bjorndahl TC; Turkoglu O; Graham SF; Wishart D; Odunsi K
    Metabolomics; 2017 Dec; 14(1):6. PubMed ID: 30830361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis.
    Zhang X; Zhu X; Wang C; Zhang H; Cai Z
    Oncotarget; 2016 Sep; 7(39):63437-63448. PubMed ID: 27566571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.
    Roś-Mazurczyk M; Wojakowska A; Marczak Ł; Polański K; Pietrowska M; Polanska J; Dziadziuszko R; Jassem J; Rzyman W; Widlak P
    Acta Biochim Pol; 2017; 64(3):513-518. PubMed ID: 28803255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study.
    Poli D; Carbognani P; Corradi M; Goldoni M; Acampa O; Balbi B; Bianchi L; Rusca M; Mutti A
    Respir Res; 2005 Jul; 6(1):71. PubMed ID: 16018807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.
    Li R; Todd NW; Qiu Q; Fan T; Zhao RY; Rodgers WH; Fang HB; Katz RL; Stass SA; Jiang F
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):482-7. PubMed ID: 17255269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving lung cancer prognosis assessment by incorporating synthetic minority oversampling technique and score fusion method.
    Yan S; Qian W; Guan Y; Zheng B
    Med Phys; 2016 Jun; 43(6):2694-2703. PubMed ID: 27277016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.